LONDON, Dec 14 (Reuters) - GlaxoSmithKline Plc's (GSK.L: Quote, Profile , Research) experimental cancer pill Tykerb works in women newly diagnosed with inflammatory breast cancer when given before surgery, researchers said on Thursday.
Results of a small Phase II study presented at the San Antonio Breast Cancer Symposium in Texas showed a high clinical response from daily treatment with Tykerb for two weeks, followed by weekly paclitaxel, or Taxol, for 12 weeks.......
Use the following link to read the complete story: Rueters.com
No comments:
Post a Comment